VKORC1 Antibody - N-terminal region : HRP (ARP63330_P050-HRP)

Vitamin K is essential for blood clotting but must be enzymatically activated. This enzymatically activated form of vitamin K is a reduced form required for the carboxylation of glutamic acid residues in some blood-clotting proteins. The product of this gene encodes the enzyme that is responsible for reducing vitamin K 2,3-epoxide to the enzymatically activated form. Fatal bleeding can be caused by vitamin K deficiency and by the vitamin K antagonist warfarin, and it is the product of this gene that is sensitive to warfarin. In humans, mutations in this gene can be associated with deficiencies in vitamin-K-dependent clotting factors and, in humans and rats, with warfarin resistance. Two pseudogenes have been identified on chromosome 1 and the X chromosome. Two alternatively spliced transcripts encoding different isoforms have been described.

UBC; ILK; ZMYM6NB; TMEM242; SNORA12; TMEM256; ZCCHC24; METTL7B; SPTSSA; VKORC1L1; CCDC167; CCDC12; TMEM45B; KCNK17; JAGN1; SERP1; PPA2; TRAM1; TREX1; YIF1A; EBP; ARL6IP5; PROCR; IFITM3; ATP6AP2; BCAP31; PDIA6; HDAC6; HOMER2; VAPB; CLDN10; DPM2; REEP5; TF

All conjugated antibodies should be stored in light-protected vials or covered with a light protecting material (i.e. aluminum foil) . Conjugated antibodies are stable for at least 12 months at 4C. If longer storage is desired (24 months), conjugates may be diluted with up to 50% glycerol and stored at -20C to -80C. Freezing and thawing conjugated antibodies will compromise enzyme activity as well as antibody binding.